KRAS multi-inhibitor
KRAS multi-inhibitor
Search
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Avenciguat (BI 685509)
Avenciguat (BI 685509)
NPY2r agonist
Food intake regulator
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
BI 765845
Heart disease modulator
Survodutide (BI 456906)
Survodutide (BI 456906)
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Pets
Pets
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Retinal Health: Meet the Scientists
We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Survodutide (BI 456906)
BI 456909
Ruminants
Ruminants
Fencovis®
Indicated for infectious diseases in cattle
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine